Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NRAS proto-oncogene GTPase is a peripheral membrane protein belonging to the Ras subfamily of small GTPases, functioning as a vital molecular switch in cellular signal transduction (UniProt, P01111). It cycles between an active GTP-bound state and an inactive GDP-bound state, a process regulated by guanine nucleotide exchange factors and GTPase-activating proteins (NCBI Gene, 4893). Once activated, NRAS stimulates downstream signaling pathways, most notably the MAPK/ERK and PI3K/AKT cascades, which are essential for regulating cell growth, differentiation, and survival (NCI Thesaurus, C17654). Somatic missense mutations, particularly at codons 12, 13, and 61, result in a protein that is locked in the active GTP-bound state, leading to continuous signaling and malignant transformation. These mutations are frequently identified in various cancers, including approximately 20% of cutaneous melanomas, as well as acute myeloid leukemia and colorectal carcinoma (StatPearls, "RAS Gene Family"). While direct inhibition of NRAS has been historically challenging due to its high nucleotide affinity, therapeutic approaches currently focus on inhibiting downstream effectors like MEK and RAF, or utilizing farnesyltransferase inhibitors to disrupt its membrane localization. Recent advancements are also seeing the emergence of direct covalent inhibitors designed to target specific mutant forms of the NRAS protein.
Inhibition of downstream signaling effectors in the MAPK/ERK and PI3K/AKT pathways, inhibition of post-translational farnesylation to prevent membrane localization, and development of direct covalent inhibitors targeting specific mutant alleles.
6 more in the full profile.
Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NRAS proto-oncogene GTPase (NRAS).